A robust method for the assessment of average bioequivalence in the presence of outliers and skewness.

Divan Aristo BurgerRobert SchallSean van der Merwe

Published in: Pharmaceutical research (2021)

As a sensitivity analysis, we recommend the fit of robust models for handling outliers that are occasionally encountered in crossover design bioequivalence data.

Keyphrases

electronic health record
open label
randomized controlled trial
double blind
data analysis